James Overell

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · The Lancet Neurology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Surgery +5

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Jerry S. Wolinsky, Douglas L. Arnold, Bruno Brochet et al. · The Lancet Neurology · 2020 · 150 citations

Medicine, Neurology, Pharmacotherapy +11

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

Jeremy Chataway, Floriana De Angelis, Peter Connick et al. · The Lancet Neurology · 2020 · 130 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Variant CJD in an individual heterozygous for PRNP codon 129

Diego Kaski, Simon Mead, Harpreet Hyare et al. · The Lancet · 2009 · 116 citations

Life Sciences, Genetics, Molecular Genetics +12